Afinitor receives EU recommendation to treat rare lung cancer
April 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis
Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …
Board at Medivation unanimously reject Sanofi bid
April 29, 2016Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover
The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …
Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer
April 29, 2016Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer
The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …
Novo Nordisk Q1 operating profit down 10% in local currencies
April 29, 2016Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results
Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …
Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results
Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
AstraZeneca Q1 earnings down 12%; maintains FY view
April 29, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Q!, earnings, outlook, profits, q, results
UK drugmaker AstraZeneca (LSE: AZN) on Friday reported a 12% drop in first-quarter earnings and said it plans to streamline …
Amgen raises 2016 outlook after Q1 earnings boost
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise
Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover
AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …
The mutual benefit of becoming one of Britain’s best workplaces
April 28, 2016Medical Communications great place to work, medical communications, medical communications agency
Imagine a company with a 100%-satisfied workforce. What could a team of such fulfilled employees really deliver to clients?
Abbott to purchase St Jude Medical in $25 billion deal
April 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing $25, 25 billion, Abbott, Medical device, acquisition, purchase, st jude medical
Abbott (NYSE: ABT) has announced an agreement to purchase device manufacturer, St Jude Medical, in a deal worth $25 billion. …
World Immunisation Week marked by ABPI reception in House of Commons
April 28, 2016Medical Communications ABPI, immunisations
The ABPI vaccine group joined a host of figures at a parliamentary reception to mark World Immunisation Week. Parliamentarians, policy …
Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises
April 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises
Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …
PTC Therapeutics appoints Tuyen Ong as chief medical officer
April 28, 2016Business Services, Research and Development
PTC Therapeutics (Nasdaq: PTCT) has named Tuyen Ong chief medical officer. He succeeds Robert Spiegel who will remain with the company …
Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud
April 28, 2016Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice
Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
SHL at the 2016 Prefillied Syringes Seminar Tokyo
April 28, 2016Manufacturing and Production
SHL is glad to announce that it is going to participate in the Prefilled Syringe Seminar 2016 Tokyo, organized by …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
New head of R&D at Biogen
April 27, 2016Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
